Results 51 to 60 of about 2,997 (217)

Galectin-3 performance in histologic and cytologic assessment of thyroid nodules. A systematic review and meta-analysis [PDF]

, 2017
The literature on Galectin-3 (Gal-3) was systematically reviewed to achieve more robust information on its histologic reliability in identifying thyroid cancers and on the concordance between Gal-3 test in histologic and cytologic samples.
Crescenzi, Anna, Giovanella, Luca, Romanelli, Francesco, Trimboli, Pierpaolo, Virili, Camilla   +4 more
core   +1 more source

Reengineered Anti-CD4 Cys-diabody Variants for ⁸⁹Zr-immunoPET of CD4⁺ T Cells in Immunocompetent Mice. [PDF]

Mol Imaging Biol
CD4+ T cells (T helper and T reg) play an important role in the immune system and are influential in autoimmune diseases (e.g., rheumatoid arthritis, inflammatory bowel disease) and cancer (antitumor immunity). Non-invasive, whole-body anti-CD4 immunoPET
Salazar FB, Tavaré R, Ökten A, Kujawski M, Wu AM, Zettlitz KA.   +5 more
europepmc   +2 more sources

[⁸⁹Zr]Zr-DFO-Trodelvy immunoPET for noninvasive Trop2 imaging in bladder cancer. [PDF]

Am J Nucl Med Mol Imaging
PURPOSE The Trop2-targeting antibody-drug conjugate (ADC), sacituzumab govitecan (TrodelvyTM), demonstrates significant therapeutic efficacy in targeting Trop2-expressing tumors.
Huang W, Sun X, Liang Y, Mixdorf JC, Yang Q, Engle JW, Xiao X, Li L, Kang L, Cai W.   +9 more
europepmc   +2 more sources

Role of noninvasive molecular imaging in determining response [PDF]

, 2018
The intersection of immunotherapy and radiation oncology is a rapidly evolving area of preclinical and clinical investigation. The strategy of combining radiation and immunotherapy to enhance local and systemic antitumor immune responses is intriguing ...
Marciscano, Ariel E, Thorek, Daniel L.J.
core   +2 more sources

Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling [PDF]

, 2016
BACKGROUND: We applied a non-linear immunokinetic model to quantitatively compare absolute antibody uptake and turnover in subcutaneous LNCaP human prostate cancer (PCa) xenografts of two radiolabeled forms of the humanized anti-prostate-specific ...
Blesida Punzalan, Daniel E. Spratt, Darren R. Veach, Edward K. Fung, Jawaria Amir, Joseph R. Osborne, Neil H. Bander, Pat B. Zanzonico, Sandhya Chalasani, Sarah M. Cheal, Shoaib B. Fareedy, Steven M. Larson, Volkan Beylergil, Wolfgang A. Weber   +13 more
core   +1 more source

Pretargeted Trop-2 ImmunoPET for Rapid, Selective Detection of Pancreatic Tumors. [PDF]

Clin Cancer Res
PURPOSE Recent clinical advances with the approval of antibody-drug conjugates targeting Trop-2 such as sacituzumab-govitecan and datopotomab-deruxtecan have garnered tremendous interest for their therapeutic efficacy in numerous tumor types including ...
Pratt EC, Mandleywala K, Bauer D, Bolaender A, Chao G, Castanares MA, Collins EC, Lewis JS.   +7 more
europepmc   +2 more sources

Cerebral rituximab uptake in multiple sclerosis: A (89)Zr-immunoPET pilot study [PDF]

, 2017
Previous studies have demonstrated that the chimeric monoclonal antibody rituximab significantly reduces clinical and radiological disease activity in relapsing-remitting multiple sclerosis as early as 4 weeks after the first administration.
Barkhof, F, Hagens, MH, Killestein, J, Lammertsma, AA, van Berckel, BN, van Dongen, GA, Yaqub, MM   +6 more
core   +1 more source

Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET

Clinical Cancer Research, 2021
Abstract Purpose: We recently identified CD46 as a novel therapeutic target in prostate cancer. In this study, we developed a CD46-targeted PET radiopharmaceutical, [89Zr]DFO-YS5, and evaluated its performance for immunoPET imaging in murine prostate cancer models.
Sinan Wang, Jun Li, Jun Hua, Yang Su, Denis R. Beckford-Vera, Walter Zhao, Mayuri Jayaraman, Tony L. Huynh, Ning Zhao, Yung-hua Wang, Yangjie Huang, Fujun Qin, Sui Shen, Daniel Gioeli, Robert Dreicer, Renuka Sriram, Emily A. Egusa, Jonathan Chou, Felix Y. Feng, Rahul Aggarwal, Michael J. Evans, Youngho Seo, Bin Liu, Robert R. Flavell, Jiang He   +24 more
openaire   +5 more sources

ImmunoPET in Multiple Myeloma—What? So What? Now What? [PDF]

Cancers, 2020
Despite constant progress over the past three decades, multiple myeloma (MM) is still an incurable disease, and the identification of new biomarkers to better select patients and adapt therapy is more relevant than ever. Recently, the introduction of therapeutic monoclonal antibodies (mAbs) (including direct-targeting mAbs and immune checkpoint ...
Bailly, Clément, Chalopin, Benjamin, Gouard, Sébastien, Carlier, Thomas, Remaud-Le Saec, Patricia, Marionneau-Lambot, Séverine, Moreau, Philippe, Touzeau, Cyrille, Kraeber-Bodéré, Françoise, Bodet-Milin, Caroline, Chérel, Michel   +10 more
openaire   +3 more sources

Development of a 64Cu-labeled CD4+ T cell targeting PET tracer: evaluation of CD4 specificity and its potential use in collagen-induced arthritis

EJNMMI Research, 2022
Background CD4+ T cells are central inflammatory mediators in the pathogenesis of autoimmune rheumatoid arthritis (RA), as they are one of the dominating cell types in synovial inflammation.
Anne Skovsbo Clausen, Camilla Christensen, Esben Christensen, Sigrid Cold, Lotte Kellemann Kristensen, Anders Elias Hansen, Andreas Kjaer   +6 more
doaj   +1 more source